Likang Life Sciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Likang Life Sciences - overview
Established
2019
Location
Beijing, -, China
Primary Industry
Biotechnology
About
Founded in 2019 and based in Beijing, China, Likang Life Sciences operates as an oncology drugs provider that provides innovative anti-tumor drugs. The Founder, Chairman of the Board, and CEO, Chen Li, graduated from Beijing Institute of Technology and served as a postdoctoral researcher in clinical medicine at the Peking University Cancer Hospital & Institute. The company has branch offices in Hong Kong and Singapore, and has cooperated with Chinese PLA General Hospital (301 Hospital), Beijing Cancer Hospital, and Cancer Hospital Chinese Academy of Medical Sciences. In February 2025, it closed a venture funding from new investor E-Town International Industrial Investment.
The company has developed the Likang tumor neoantigen epitope analysis platform (LNEA). Products include LK101 injection, dendritic cell drugs (DC), genetically modified T cells (TCR-T), new antigen-specific T cells (Neo-T), etc. The company generates revenue by providing cancer treatment service and oncology drugs.
Current Investors
SF Express, Zhuhai Yongtong Technology, E-Town International Industrial Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.likanglife.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Likang Life Sciences - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.